These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19010686)

  • 1. Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2009 Jan; 17(1):284-94. PubMed ID: 19010686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
    Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.
    Rao D; Li H; Ren X; Sun Y; Wen C; Zheng M; Huang H; Tang W; Xu S
    Eur J Med Chem; 2021 Jul; 219():113393. PubMed ID: 33845236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives.
    Hisamichi H; Naito R; Toyoshima A; Kawano N; Ichikawa A; Orita A; Orita M; Hamada N; Takeuchi M; Ohta M; Tsukamoto S
    Bioorg Med Chem; 2005 Aug; 13(16):4936-51. PubMed ID: 15990316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines.
    Alberti MJ; Auten EP; Lackey KE; McDonald OB; Wood ER; Preugschat F; Cutler GJ; Kane-Carson L; Liu W; Jung DK
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3778-81. PubMed ID: 15993060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structure, regulation, and function of ZAP-70.
    Au-Yeung BB; Deindl S; Hsu LY; Palacios EH; Levin SE; Kuriyan J; Weiss A
    Immunol Rev; 2009 Mar; 228(1):41-57. PubMed ID: 19290920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
    Gopalsamy A; Ciszewski G; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 May; 19(10):2735-8. PubMed ID: 19362830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
    Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA
    Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2008 Aug; 16(15):7347-57. PubMed ID: 18585046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
    Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships.
    Horiuchi T; Chiba J; Uoto K; Soga T
    Bioorg Med Chem Lett; 2009 Jan; 19(2):305-8. PubMed ID: 19091560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
    Wu Z; Hartnett JC; Neilson LA; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Hartman GD; Bilodeau MT
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1274-9. PubMed ID: 18249537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.